Portevo
US Companies
ABBVNew York Stock Exchange

AbbVie (ABBV) financial results

Report publication dates, analyst consensus, and how AbbVie's share price reacted to previous earnings — all in one place, in English.

Updated: October 11, 2026

Share Price
276.47 USD
+1.49%
Market Cap
$488.55 bn
Next Report
October 30, 2026
confirmed date
Earnings Beat
75%
out of 4 last quarters
Average Share Price Movement
5.43%
on the session after publication
P/E Ratio
78.10
AbbVie's performance vs. estimatesThe company beat analyst forecasts in 75% of the last 4 quarters.75%above forecasts
Percentage of quarters in which AbbVie's earnings beat analyst consensus — from the last 4 reports.

When AbbVie releases earnings

AbbVie's next earnings report is scheduled for October 30, 2026, according to the company's announcement.

The expected earnings per share (EPS) is 3.79 USD. Analyst forecasts range from 3.61 to 3.86 USD. The market reacts not to the absolute earnings, but to the difference between the actual result and this forecast.

Expected revenue: 17.32 B USD.

AbbVie's latest earnings report: what the numbers showed

AbbVie's last reported quarter ended June 30, 2026. Revenue was $16.99 billion, and net income was $3.61 billion. EPS reached $3.65 compared to analysts' forecast of $3.61, exceeding expectations by 1.15%. The share price changed by -4.78% on the first trading day after the release.

Revenue
$16.99 bn
for the quarter
Net income
$3.61 bn
for the quarter
EPS
3.65 USD
forecast 3.61
Surprise
+1.15%
vs. consensus
Share price after report
-4.78%
next trading day
Net margin
21.27%
net income to revenue

Insider Transactions: AbbVie

Who from the management board, supervisory board, US Congress, or government bought and sold shares of this company — based on official filings.

Insider Buys · 12 mo.
26
≈ $628K
Sales · 12 mo.
27
Unique individuals
12
in the last year
Last transaction
September 14, 2026
Latest transactionsForm 4, STOCK Act, OGE, MAR
Donald Trump
Donald Trump · buy ABBV
$50K–$100KJuly 31, 2026
Donald Trump
Donald Trump · buy ABBV
$50K–$100KJuly 23, 2026
Donald Trump
Donald Trump · buy ABBV
$1K–$15KJune 23, 2026
Nicholas Donoghoe · sell ABBV
$8.2M August 14, 2026
Donald Trump
Donald Trump · buy ABBV
$50K–$100KJune 16, 2026
Donald Trump
Donald Trump · sell ABBV
$1K–$15KMay 18, 2026
Donald Trump
Donald Trump · sell ABBV
$100K–$250KMay 18, 2026
See insider faces on the chart in the app →

How the stock reacted to past earnings

The company beat analyst estimates in 75% of the last 4 quarters.

The average share price change on the day after earnings release is 5.43% — regardless of direction. The largest move was 7.12%. This number says more about the risk of holding a position through an earnings report than the earnings forecast itself.

AbbVie share price reaction to earningsBar chart: AbbVie share price change on the trading day after the last 4 earnings releases. Increased after 1 of them, decreased after 3. Largest movement: 7.12%.-7.12%X 25-2.94%Feb 26+6.89%Q26-4.78%Q26
AbbVie share price change on the trading day after the report's release. Green bar indicates an increase, red indicates a decrease.
EPS Forecast vs. Actual — AbbVieBar chart comparing EPS forecasts with AbbVie's actual results over the last 4 quarters. Actual results exceeded forecasts in 3 of them.1.781.86Q3 252.652.71Q4 252.672.65Q1 263.613.65Q2 26analyst forecastCompany earnings
AbbVie EPS: analyst forecast and actual result, in USD.
AbbVie quarterly results — forecast, actual, and share price performance on the day of release. EPS values in USD.
QuarterRelease dateEPS estimateActual EPSSurpriseShare price reaction
June 30, 2026July 31, 20263.613.65+1.15%-4.78%
March 31, 2026April 29, 20262.672.65-0.77%+6.89%
December 31, 2025February 4, 20262.652.71+2.16%-2.94%
September 30, 2025October 31, 20251.781.86+4.23%-7.12%

How much this company's stock moves after earnings

AbbVie's share price changes by an average of 5.43% on the first trading day after earnings releases — based on the last 4 reports, regardless of direction. This ranks 90 out of 180 companies for which we calculated this statistic.

Analyst forecasts for upcoming periods

The consensus is the average of many analysts' forecasts. The more analysts behind a number, the less likely it is to be a single error—but forecast agreement is never a guarantee of the actual result.

Forecasts for AbbVie — EPS values in USD.
PeriodEPS estimateEPS a year agoChangeRevenue forecastAnalysts
Current quarter3.791.86+104.02%$17.32 bn18
Next quarter3.882.71+43.17%$18.28 bn17
Current year13.9810.00+39.85%$67.60 bn26
Next year16.2613.98+16.25%$73.55 bn25

Revenue and margins quarter by quarter

Margin shows how much of sales a company retains. Rising revenue with shrinking margins means growth is coming at the expense of profitability—and that's usually more interesting than sales growth alone.

AbbVie Revenue and MarginBar chart of AbbVie's quarterly revenues for the last 5 quarters; revenues are growing, with the overlaid line showing net margin.Q2 25Q3 25Q4 25Q1 26Q2 266.08%1.18%10.93%4.63%21.27%Quarterly revenueNet margin
AbbVie quarterly revenues in USD and net margin for the same quarter.
AbbVie Quarterly Earnings
QuarterRevenueGross marginOperating marginNet margin
June 30, 2026$16.99 bn74.74%39.57%21.27%
March 31, 2026$15.00 bn71.88%31.56%4.63%
December 31, 2025$16.62 bn72.61%34.96%10.93%
September 30, 2025$15.78 bn66.38%29.06%1.18%
June 30, 2025$15.42 bn71.82%37.07%6.08%

AbbVie Dividend

AbbVie's next ex-dividend date is October 15, 2026. To receive this payment, you must own shares by the end of the trading day before this date; buying on the ex-dividend date is too late.

Note: The payout ratio is 190.40%, meaning AbbVie paid out more than it earned—either from savings, debt, or a one-time gain. Such a dividend may not be repeated next year.

Dividend Yield
2.54%
from the last payment
Per Share
6.92 USD
annually
Payout Ratio
190.40%
portion of profit returned to shareholders
Ex-dividend date
October 15, 2026
next

Who Reports in the Coming Weeks

Dates from the Portevo calendar — companies in the same industry are listed first, as their earnings often move the share prices of their peers even before their own reports.

About AbbVie

AbbVie Inc. is listed on the New York Stock Exchange under the ticker ABBV, and its headquarters are in the United States. The company belongs to the healthcare sector (industry: Drug Manufacturers - General).

  • Ticker: ABBV
  • Exchange: New York Stock Exchange
  • Trading Currency: USD
  • Sector: healthcare
  • Number of Analysts Providing Estimates: 28
  • 52-Week Range: 190.75 – 277.60
  • Company Website: https://www.abbvie.com

Frequently Asked Questions

When does AbbVie release earnings?

The next report is scheduled for October 30, 2026.

What were AbbVie's earnings last quarter?

For the quarter ended June 30, 2026: revenue 16.99 billion USD, net income 3.61 billion USD, EPS 3.65 USD. This was +1.15% above analyst forecasts.

What is AbbVie's ticker symbol?

ABBV — on the New York Stock Exchange. You may also see ABBV on quote services.

What is the EPS estimate for AbbVie?

The analyst consensus for the upcoming quarter is $3.79 per share. Individual forecasts range from $3.61 to $3.86.

How much does AbbVie's share price usually change after earnings?

On average, 5.43% in the session after publication, counting both directions. The largest recorded movement was 7.12%.

Does AbbVie usually beat analyst estimates?

In the last 4 quarters, results exceeded forecasts in 75% of cases. History does not predict the next report, but it shows how cautiously analysts approach this company.

Where can I check AbbVie's financial results in English?

On Portevo — the earnings calendar, analyst forecasts, surprise history, and share price reactions are available for free and without an account.

Other companies in the healthcare sector

A company's earnings are most informative when compared to competitors in the same industry — this shows whether a weak quarter was a company-specific issue or a market-wide trend.

Related

Track AbbVie on Portevo

The company page in the app includes a price chart, indicators, and industry comparisons. Add a company to your watchlist, and its report will be highlighted in the earnings calendar—along with the rest of your portfolio.

Portevo is not an investment advisor. The data and analyses are for informational and educational purposes only and do not constitute a recommendation or an offer to buy or sell financial instruments. Quotes are from external providers and may be delayed. You make investment decisions at your own risk.

Portevo App

Your entire portfolio, company earnings, and insider trades in one place

Upload your XTB report or add companies manually — Portevo will calculate your net profit after costs, show you the earnings dates for your companies, and display insider faces on charts.

  • Portfolio with Net Profit After Costs
  • Earnings Calendar for Your Companies
  • Pelosi, Trump, and CEO Trades on a Chart
  • Works in Browser and on iPhone

No credit card required. A demo portfolio is available immediately; create your own by uploading a report.

Portevo Portfolio: Value, Net Performance, and ChartCompany Earnings Calendar in the Portevo AppETF Fact Sheet with Quotes in PortevoTransaction History and Portfolio Tracking in Portevo
Portevo — free portfolio, earnings, and insider tradesOpen App